BioNTech mRNA Cancer Drug Fails First Primary Endpoint in Head and Neck Trial, Stock Slides

BioNTech's mRNA-based cancer therapy missed the first of two dual primary endpoints in a mid-stage clinical trial targeting head and neck cancer, the company disclosed on October 13. The drug, BNT113, is being evaluated in combination with pembrolizumab against pembrolizumab alone in patients with HPV16-positive, PD-L1-expressing head and neck cancer. The failure to clear the first co-primary endpoint in the interim analysis marks a significant setback for BioNTech's broader push to extend mRNA technology into solid tumor oncology beyond its COVID-19 franchise.

Shares of BioNTech fell following the announcement, continuing a difficult stretch for the company's cancer pipeline. The result compounds pressure on investor confidence in mRNA oncology approaches after earlier trial setbacks across the sector.

Separately, Walmart announced it will cover select GLP-1 medications, including Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, as well as certain insulin products and inhalers, at no cost for its employees. The retail giant's move represents one of the most significant expansions of employer-sponsored drug benefits for weight and diabetes management to date.